Home / Transcripts / Hims & Hers Health, Inc. (HIMS) · August 10, 2026

Hims & Hers Health, Inc. (HIMS) Earnings Call Transcript

August 10, 2026

New York Stock Exchange US Health Care Health Care Providers and Services earnings 63 min

Earnings Call Speaker Segments

William Newby executive
#1

Hello, everybody, and thanks for joining us on this afternoon for the Hims & Hers Health Q2 2026 earnings call. Joining me are Andrew Dudum, who is our Co-Founder and Chief Executive Officer; Yemi Okupe, our Chief Financial Officer; and Mo ElShenawy, our Chief Technology Officer. Before turning things over to Andrew, I must go over the legal safe harbor and cautionary declarations with you. A number of statements and projections regarding future results that appear in this presentation are forward-looking statements. They rest on, among other things, how we currently see the market, competitors and regulatory expectations, and they carry risks and uncertainties that might make actual results differ materially. We are under no obligation to publicly update any forward-looking statement following this call, whether because of new information, future events, changes in assumptions or otherwise. The risks, uncertainties and other factors that might make actual results differ from our forward-looking statements are laid out in our earnings release and SEC filings. For a discussion of these risk factors as they relate to forward-looking statements, please look at our recent earnings release and our most recently filed 10-K and 10-Q reports. In today's presentation, we also include certain non-GAAP financial measures; please refer to the reconciliation tables to the most directly comparable GAAP financial measures contained in today's press release. This information, along with a link to today's webcast, is available at investors.hims.com. Following the call, this webcast will remain archived on the website for 12 months. With that said, I'll hand the call over to Andrew.

Andrew Dudum executive
#2

Thank you, Bill. Hello, everyone, and I appreciate you joining us this afternoon. During this quarter, we achieved meaningful advancement in creating a health experience unlike anything before it, one that demonstrates delivering world-class care access globally at a fair cost is achievable. As more customers come to us and our impact on the sector grows stronger, we are proving that a company can simultaneously care for individuals and generate profit. Before Yemi takes us through the financial details, I'd like to emphasize three primary areas fueling our ongoing expansion. First, what we're putting into AI and technology is producing a health experience that, in our view, cannot be duplicated by any other organization. Our CTO, ElShenawy, has joined us today to explain how this is materializing through stronger customer connections and greater operational efficiencies. Second, because of our exceptional infrastructure, we're able not only to serve customers across a wider range of needs from start to finish, but also to move into more intricate categories safely, more quickly, and at larger scale than competitors; and third, combining our worldwide footprint with our technology and infrastructure has produced a platform demonstrating to both customers and industry leaders that high-quality care access can be individualized yet broadly available. Hims & Hers is creating something completely novel, and copying it is becoming harder all the time. Close to 3 million customers share our belief in a health future that is proactive, personal, and designed around their lives, and we're delighted to serve as the partner delivering it to them daily. Let's begin with our AI investment. By integrating AI throughout the whole platform, we will provide a unified, AI-native health experience that we believe no competitor or LLM can equal. Mo, our CTO, will describe what this means for our customers and the early wins we've achieved, but I want to begin with the reasoning. The reason we're pursuing this strategy, and the reason we're confident it's the route to vastly enhancing care for customers everywhere; during Q2, we gained over 300,000 subscribers, which lifted our worldwide subscriber total to close to 3 million individuals. For perspective, the patient population we now serve is comparable to that of some of the biggest health care systems in America; and in contrast to frontier AI businesses that numerous people presently turn to for everyday guidance, we guide customers through the whole health journey, starting with their initial question and continuing through clinical treatment and ongoing follow-up care; that complete, closed-loop connection, paired with our scale, is extraordinarily potent. Customer trust cannot be purchased; it must be won; over 9 years, millions of individuals have placed their confidence in Hims & Hers to assist them in feeling at ease pursuing care for conditions that ought to be normalized. That confidence has been built through paying attention to what worries them, coming up with answers that address those worries, and producing results repeatedly, area by area, across 9 years of information that strengthens what we know about which approaches help which people, and the reasons behind that. This gathered knowledge is the thing that sets our platform apart. It runs on the millions of customers who've demonstrated to us the real power of excellent care, which is exactly why they place their faith in us for whatever lies ahead. Rival health firms focus on trivial things. They bolt small enhancements onto the current setup, whereas we are rebuilding our platform to be fully AI-native, enabling it to offer a seamless experience that feels dynamic and tailored — one in which AI coaches and support agents, a care team, a clinician and a pharmacy operate as a single coordinated structure pursuing one aim: helping people stay healthy. Those we serve don't merely inquire about their wellbeing or look for particular treatments via our platform. They embark on an extended path alongside us; and we think the intelligence being developed around that connection will position Hims & Hers as their go-to everyday health partner. I'd like to hand things over to Mo now to discuss in greater detail how this is becoming reality.

Mohamed ElShenawy executive
#3

Thanks, Andrew. What sets us apart is an AI-first engineering approach — not merely tacking on a capability, but fundamentally rethinking how the customer journey works. AI is becoming essential infrastructure rather than a nice-to-have; we're swapping out the old telehealth playbook for a brand-new approach in our sector, a single, connected care experience in which each customer's care team operates from one system that already has their history. There are no portals, nobody starts from scratch, and nobody has to re-explain their situation to something that only offers generic guidance. Instead, care is tailored to the individual, informed by data, provided by clinicians and enabled by frictionless technology. That represents the core customer experience, and our intention is to extend it across the full platform in time. It draws on our closed-loop data, and it's turning into the foundation for personalization throughout the whole journey — smarter outreach, earlier risk signals and tools that let providers customize treatment for every patient. This approach is already producing results for our customers and for our business, and I want to cover both. First, the AI-native experience we recently introduced for Hers weight loss customers is creating real change for the people who seek care from us. A phased rollout started in early July, and the impact showed up right away. Customers started interacting more frequently. On the new care experience, Hers users are sending three times as many messages through the platform, and AI is answering 80% of their inquiries to help them through treatment. As a result, nonclinical work our support teams deal with—things like order status updates and routine questions about side effects—has been reduced by almost half thanks to AI. We recognize that when engagement is low and adherence is weak, outcomes tend to suffer, so it's encouraging to see customers holding richer, more deliberate conversations while our care teams aren't under added pressure. There's another benefit: clinical matters, including dosage tweaks or changes to treatment, can be identified and brought to a provider's attention faster, which means earlier intervention that helps keep our customers on the right path. In just a handful of months, the changes we made internally have proven so effective that our reliance on third-party agentic AI customer support providers has dropped dramatically. Eventually, we expect to eliminate them altogether; what we've built is a clinically grounded agentic AI customer support experience that we think delivers better service to our customers. We're excited to bring that experience to more customers worldwide, and we feel we're moving closer to a day when the model we're developing becomes the backbone for health platforms beyond Hims & Hers. On top of that, we continue to put money into our core technical foundation, reworking key components so that updates to customer flow, product fulfillment and catalog management are each modular. Because of this, we can introduce fresh offerings and enter new regions far more quickly than before, and we do so more cheaply—something that in the past translated into savings we passed along to buyers. The developments we're observing right now represent just the beginning of AI being woven into every phase of how customers interact with us. It's precisely these initial signals that have led us to increase our investment so that this experience becomes a reality for all of our customers. Over the next few months, our plan is to bring new AI talent onto the team, keep growing the talent we already have, and launch an AI R&D lab in Menlo Park, so the group behind this innovation can collaborate in the middle of Silicon Valley. We anticipate that this spending will recoup itself quickly. And crucially, our aim here isn't to swap out providers — it's to lift them up. We care deeply about making sure clinicians stay involved and remain the ones making clinical calls. At Hims & Hers, AI lifts the routine tasks from clinicians' shoulders, freeing their time for judgment, complexity, and the person sitting in front of them. The AI we use stays inside the clinical protocols and guidelines our medical experts establish — it doesn't roam the open Internet. And we've built it so that every single interaction with the AI can be traced and audited. Why take this approach? Because we see AI models becoming a commodity, and on their own they're only one incomplete component of a wider health experience. If you want an AI infrastructure that dependably improves clinical outcomes, the only way to get there is by tracking those outcomes. As we see it, no other company but ours operates a closed loop at this scale that stretches across intake, treatment, follow-up and outcome. And from every part of that loop, the system absorbs lessons. We think this will prove transformative for our business too. As this new experience reaches more customers, we anticipate gains in both the quality and depth of care people get on the platform, which will in turn retain customers with us for longer and draw new ones in. We think this is something that only we are capable of doing well. What sets us apart is being a daily partner to customers, not merely a chatbot sitting on their home screen. We accompany our customers across their whole journey, assisting them in locating qualified providers and treatments that work. We've built an AI infrastructure capable of learning not just what succeeds, but what succeeds most effectively for every individual; and we possess the scale to apply this across millions of customers worldwide, generating a continuous loop of enhancement. Superior care leads to superior insight, and superior insight leads to superior care. That's the way we're transforming what the world believes is achievable in health, and we've barely begun. I look forward to returning next quarter with news about the advances we'll keep making in this area. Thank you.

Andrew Dudum executive
#4

Thank you, Mo. Now let's turn to the second topic we're covering today: how our capacity to serve the individuals who place their health in our hands keeps expanding, and why that has never been more important. Because we invested years into constructing infrastructure that nobody else possesses, we're able to assist clients from the very start through to the end, across a broad range of requirements. That's what allows us to keep moving into increasingly sophisticated categories, offering solutions that are more personalized and easier to access — and it will continue to. This underpins those strong customer bonds I've frequently mentioned. More and more, those we serve entrust their care to us for multiple conditions at once, and every new need they bring onto the platform deepens their confidence in us and lengthens the duration of our relationship. We think nobody is better positioned to assist millions of individuals in taking a proactive approach to the more complicated health issues that frequently remain unnoticed or unaddressed. A compelling illustration is testosterone. The majority of men with low testosterone are unaware of it, attributing their symptoms to tiredness or getting older; we created an experience that alters that — blood draws done at home, tracking over time, and treatment guided by providers that adjusts as things progress. And that experience is clearly connecting with people. Just 3 quarters following launch, testosterone is growing more quickly than any other specialty besides weight loss. That's why we have genuine conviction in our capacity to broaden into injectable and oral TRT prior to the close of this year, and also to carry this approach into additional specialties; it's one reason we've brought on Dr. Anant Vinjamoori as our new Chief Medical Officer of Hims, who joins the outstanding group of medical leaders under Dr. Pat that forms our clinical foundation. Dr. Vinjamoori brings over 10 years of clinical experience spanning internal medicine, primary care and longevity, and that will be essential to how we develop and grow our offerings in areas such as hormonal health, longevity medicine and peptide therapy. The value and credibility of his perspective among industry leaders and regulators was made clear by his involvement in the recent PCAC hearing. His knowledge will also play a core role in how we speed into our next phase. We've built the infrastructure needed to win in more complex categories: more than 1 million square feet of pharmacy and lab testing facilities, extensive know-how in sterile compounding, and worldwide reach. Our verticalization work aims at providing a superior, higher-quality experience at a cost nobody else can equal, which leads me to peptides. When a category is exploding in popularity while the market can't figure out a safe, sustainable means of supporting it, that's precisely the moment where our scale, infrastructure and ecosystem excel. Right now we're building a best-in-class peptides experience, encompassing products made in the U.S., guidance led by clinicians, and continuous blood testing. As we await the FDA's ruling on the 6 peptides recommended at last month's PCAC hearing, we've begun validation and stability testing on APIs for those peptides produced at our Menlo Park facility. That way, should the FDA give the green light for compounding, we can deliver them to market backed by a supply chain that is both safe and verified. Until then, our plan is to provide access to peptides that are already permitted, supported by supply chains that are safe and well-established, prior to the close of this year. Among those will be options such as sermorelin, glutathione and NAD+. Last, I want to talk about our third growth area, the one that supports everything we've covered so far today: our global scale. What our platform promised began with what we could deliver for U.S. customers, a market where five specialties each run above a $100 million annual run rate. That full experience is now being extended to customers worldwide. When we completed our acquisition of Eucalyptus in June, we became the top global consumer health platform. It stands as the biggest acquisition ever undertaken by our company, and we now operate in three international markets beyond the U.S., each also pacing above a $100 million annual run rate. This represents the evolution of the company we always believed could happen. For the first time, one platform is capable of providing a genuinely personal, accessible and effective weight management experience to customers everywhere, whether their home is Boston, Bristol or Byron Bay. Our intention is to make that a reality for customers across all our specialties, and I'm eager to share more about our global plans with everyone on future quarterly calls. We can build sticky relationships with millions of customers globally, and we think that renders us invaluable to our industry partners. The strength of our relationship with Novo Nordisk has been a source of real excitement. By partnering with the top innovators in one of the highest-demand categories, we're broadening our addressable market, and we're eager to find ways to collaborate with other partners of the same caliber. Today, we're providing more people access to a world-class weight loss experience than any other digital platform anywhere. That isn't merely evidence of our scale. It's proof that health care is at last embracing the consumer-centric model already standard in industries including entertainment, travel and transportation. We're spearheading a transformation that strips out the middle layers and makes sure access flows directly from innovators to consumers. In our view, our expanding scale along with rising investment in our technology and infrastructure makes us structurally more efficient than any other player in health care; we intend to keep leveraging our leadership position to deliver greater value to customers at better prices. To put it more plainly, we're playing offense, and our balance sheet and cost structure let us sustain that in a way others cannot. This marks the beginning of what our platform will deliver for our customers and our industry partners alike. We think we're getting close to a time when everyone can get preventive screenings, the new drugs that help us feel our best, and a care team backing our journey — and all of that at a monthly cost people can handle, shaped around the life each of us truly leads. To close, I'd say one idea defined this quarter: proof. Evidence that a top-tier health experience can be delivered worldwide at a fair price, evidence that stronger ties with customers and a business that turns a profit don't work against each other; each makes the other stronger. We're demonstrating that Hims & Hers is where people find the industry's most complete personal health offering. Close to 3 million individuals depend on us every day, and that duty is far too large to handle with anything short of the finest technology, infrastructure, treatments, providers and platform we're capable of delivering. I've told you before that we're creating the future of health, yet that future has never been nearer, and that's thanks to the progress we're making for our customers daily. I'll hand things to Yemi now so he can take you through the financials.

Yemi Okupe executive
#5

Thank you, Andrew. I want to take you through what we accomplished during the second quarter on each of our main growth drivers, plus the investments we're funding to deliver an improved health experience for millions of consumers around the world and to seize the enormous opportunity ahead of us. In Q2, total revenue climbed almost 40% compared with the same period a year earlier, reaching over $753 million. A wider product selection, additional geographic markets, and a stronger consumer experience helped us bring in 300,000 net new subscribers, finishing the quarter with close to 3 million subscribers on our platform. U.S. revenue growth picked up to 16% year-over-year during the second quarter, with domestic operations producing $622 million in revenue. The strategic shift we executed in March to broaden the range of branded weight loss products available on our platform served as a major catalyst for the renewed acceleration in Q2, since higher subscriber additions more than compensated for revenue recognition headwinds caused by moving branded weight loss offerings to a monthly cadence. More and more, we regard specialties that draw large audiences — weight loss and sexual health among them — as strategically vital for reasons going beyond the revenue they generate directly, because they deliver benefits such as, first, a substantial widening of cross-sell opportunities throughout the platform, given that consumers frequently pursue treatment for conditions unrelated to weight. That cross-sell potential grows even larger as we broaden the reach of lab testing on our platform, which is able to uncover underlying treatment needs in specialties such as low testosterone and cardiovascular health that subscribers might be unaware of and would not otherwise pursue. A course of care that begins with obesity medication may end up serving as a way to connect subscribers with a much broader range of health services. Next, it gives us a fast way to expand the organized information we hold across the platform. As our subscriber base expands, the worth of that information rises. With it, providers get resources that help them match subscribers more successfully to effective therapies, and we can create more personalized offerings for continued care. Each new subscriber sharpens the platform, improving it for the next person. Last, we built our infrastructure so it would keep delivering growing returns as we scale. When more people sign up, we get better at running the whole operation—things like our network of providers, filling prescriptions, and the care we provide afterward. Because serving each person costs us less, we can offer reasonable prices to even more subscribers. Since our business here at home is doing so well, we felt confident enough to put money into markets overseas and introduce what we offer to millions of buyers in other nations. In Q2, revenue from outside the country came in at $131 million, which is over seventeen times higher than the same stretch a year earlier. We added the Eucalyptus team in June, which made us stronger in Europe and let us serve more customers in Australia and Japan. During Q2, Eucalyptus contributed about $40 million in revenue, which gave an extra boost to our international business—already performing strongly—as it posted 13% growth quarter-over-quarter on an organic basis. Across specialties, and now across geographies too, our revenue base continues to diversify at a fast clip. This year, Hers is expected to generate more than $1 billion in revenue, while newer specialties such as low testosterone remain potent drivers of growth for Hims. Looking ahead to upcoming quarters, we in fact expect testosterone to become the sixth U.S. specialty of ours to reach a $100 million annual revenue run rate. And with our international operations continuing to expand, this diversification becomes even more pronounced. In the U.K., Australia, and Germany, annualized revenue has already surpassed $100 million in each market. Canada is similarly tracking toward becoming part of that same group as our generic weight loss offering expands. We believe our infrastructure is capable of enhancing both the overall quality and efficiency of the platform as we continue scaling. Our aim is to keep driving scale forward, but to do so with care, laying the foundation for dependable EBITDA and cash flow generation. That discipline is evident in what we delivered for the second quarter. For the quarter, adjusted EBITDA reached $60 million, which represents an 8% adjusted EBITDA margin. That was a 1-point gain versus the prior quarter, since operating leverage more than made up for gross margin headwinds caused by the continuing mix shift toward weight loss and rising revenue contributions from our international business. Those results leave out roughly $81 million of nonrecurring costs taken during the quarter, made up of acquisition and transaction costs tied mainly to closing our Eucalyptus acquisition, restructuring costs after the strategic pivot in our weight loss specialty earlier this year, and legal contingency accruals connected to recent litigation with the FTC. Let me speak to that last point briefly and directly. In our filings, we shared that the FTC filed a complaint on July 29, which came after nearly 3 years of working together during their investigation and a number of months of settlement talks conducted in good faith. Ultimately, we couldn't agree to conditions that, in our view, don't align with either the facts or the law. Our confidence in our stance is strong, and we intend to fight this hard. During the quarter, these one-time expenses primarily affected G&A, along with operations and support costs. Except where I say otherwise, everything else I discuss today is based on our results without those costs. Adjusted gross margins came in at 64% for Q2, roughly 6 points lower than the prior quarter. The way those margins are coming down is the result of choices we made on purpose, aimed at growing the specialty categories and geographic regions we think will create value for our platform over the long haul. In our view, no other company in consumer health brings the same combination of reach, capabilities, and financial strength to make this kind of commitment. With branded weight loss offerings and sales from outside the U.S. accounting for a bigger share of what we do, we anticipate that gross margins will stay under where they have been in the past. Our focus is on keeping the unit economics at the heart of the platform solid, while making sure every one of these moves brings in more subscribers we can serve and sets us up to capture efficiencies throughout the platform as time goes on. Over the past several quarters, we've directed a significant share of our spending toward technology and G&A, pushing further into our engineering and AI teams as well as the leadership talent we need to bring a first-of-its-kind health experience to consumers worldwide. That spending won't stop, though it was encouraging to observe modest sequential leverage in both of those lines during this quarter, which in our view is an early indicator that these investments can become meaningfully accretive over time. Those same investments are starting to produce cost savings in other parts of the business as well. Operations and support gave us three points of sequential leverage in Q2. This shows gains in how efficiently our pharmacy side runs as volume grows, plus some initial cost reductions tied to the AI tools we've deployed for customer support. Per Mo, trials that succeeded demonstrated AI can eliminate half of the nonclinical work our support staff members perform. That same trial's early data also indicates participants who subscribe are more engaged and cancel less often. Once these tools become more advanced, we expect the subscriber experience overall to improve even as serving them costs us less. Finally, our marketing spending keeps yielding more efficiency as we expand. Marketing represented 34% of revenue, which is 5 points better than a year ago and 2 points better than the prior quarter.

Yemi Okupe executive
#6

A lot of what’s driving our business is still in line with what we saw in prior quarters: better retention, stronger cross-sell rates that build naturally across the platform, and years of brand building. Those things are helping us bring in customers through cheaper channels. That said, there are also two fresh dynamics creating extra opportunities. To start, our work with drugmakers that innovate, such as Novo Nordisk, is producing genuine marketing momentum. We’ve watched breakthrough therapies pull huge consumer interest toward areas such as weight loss, and when someone searches for a reliable, welcoming place to begin, they’re more and more likely to choose Hims & Hers. The platform we created keeps health straightforward, tailored, and simple to stick with, and because of that, we can convert curiosity among consumers into new care relationships with growing efficiency. On top of that, because we now operate in more countries, we can pursue bigger worldwide brand moments and enjoy much more flexibility about where we put capital to raise awareness of our platform. We think we’re at one of the most thrilling points in our company’s history—one that requires us to invest aggressively, move quickly on the right M&A deals, and bring in the kind of talent that lets us seize the substantial growth runway ahead. Every so often, this long-term way of thinking will show up in our GAAP results, and that’s what happened in the second quarter. On a GAAP basis, net income came in as a loss of $86 million, hit by the nonrecurring acquisition, restructuring, and legal costs I mentioned earlier. Across the past 12 months, our platform produced more than $260 million in operating cash flow, and that figure includes second quarter results, when the momentum in operating cash flow paused because of higher working capital needs tied to our branded weight loss offering, which is growing quickly. In the quarter, operating cash flow came to negative $36 million, while free cash flow came to negative $68 million. Since the first quarter ended, we finished two moves that we think will keep our balance sheet from getting in the way of grabbing the growth opportunities ahead. The first was setting up a $400 million receivables facility, which gives us a streamlined way to turn the expanding pool of short-dated receivables from our branded weight loss offering into cash, with capacity that grows as the business does. The second was finishing a convertible debt offering of more than $400 million, which gives our balance sheet additional strength. We expect free cash flow generation to pick back up in the second half of the year. Once we factor in the roughly $225 million upfront payment made when Eucalyptus closed, we finished the quarter holding over $840 million in cash and short-term investments. We still have $225 million left under our share repurchase program, which keeps giving us the option to act whenever we think the market value of our stock has separated from its intrinsic value. All things considered, the strength of our balance sheet, combined with our ability to tap cost-effective liquidity sources and the cash our domestic operations produce, means we have room to maneuver in funding a platform that is picking up speed, while still putting money to work confidently. Our capital deployment will keep focusing on the strategic growth levers at the heart of our business, and we're confident these will lock in the trajectory toward our 2030 financial targets. Those levers include using technology to raise the standard of care we deliver to users, moving into additional specialties, widening the availability of personalized care across those specialties, drawing on partnerships so we become a top-tier curator of health services, and growing beyond the U.S. Let me call out a handful of these areas where we anticipate the heaviest spending in the near term. To begin, we're stepping up what we put into our technology and AI capabilities. The AI work happening on our platform is producing a substantially improved consumer experience, which in turn is bringing down cancellations. Members can obtain quicker responses to their inquiries, together with an experience that feels more consistent and tailored to them. Already, early indicators show that AI can boost how efficiently we serve our members. Over time, we anticipate these gains will build on one another, delivering a potent mix of faster revenue expansion and reduced costs. We anticipate that the money spent on AI will be recouped in 12 to 18 months. Even more significantly, we think these capabilities, paired with our scale, give us structural edges that let us invest in ways competitors simply can't, particularly in key growth areas such as weight loss and international markets. Beginning with weight loss, a share of the efficiency gains from AI will be channeled into positioning our platform as the easiest place for consumers to start their weight loss journey. Our AI initiatives keep delivering wins. By the close of the year, we anticipate unlocking additional value for our weight loss subscribers through reduced prices and/or extra tools. This is a playbook we know well. In our sexual health and hair loss specialties, scale let us methodically bring prices down for our customers, which widened our addressable market, bolstered retention and in the end generated stronger LTVs and margin expansion. We see a comparable opportunity emerging in weight loss, where our expanding scale, better operational efficiencies and an AI-supported care model allow us to make treatment more affordable for a greater number of people. Providing more while charging less is how we widen the advantages of our platform, and we think hardly anyone in consumer health is set up to match that; we also intend to redirect part of those efficiencies toward speeding up growth in our international business. We possess the talent required to substantially reshape how consumers meet their health and wellness needs in Australia, Japan, Canada, Germany and the U.K. And we plan to spend aggressively in those markets as we establish category leadership. Crucially, uptake of weight loss solutions in many of those markets still trails the U.S. by a wide margin, and the very same investments aimed at reinforcing our leadership position can speed up growth of the category as a whole, enlarging the market both for us and for our industry partners. We anticipate that, once these markets reach scale, they will become significant sources of profit. In addition, we'll keep putting money into the operational strengths and clinical supervision needed so that we can responsibly add new offerings to the platform — among them more complex options such as injectable testosterone in the near term, and peptide therapies should the regulatory environment permit. That said, let me take you through what we see for the rest of the year; for the third quarter, our expectation is revenue between $880 million and $900 million, which works out to a year-over-year rise of roughly 47% to 50%. Adjusted EBITDA should land somewhere between $75 million and $95 million, which equals an adjusted EBITDA margin of 10% at the midpoint of both ranges. Looking at the full year, we are lifting our 2026 revenue outlook to $3.1 billion to $3.3 billion, which works out to a year-over-year rise of 32% to 41%. Our expectation is that 2026 adjusted EBITDA will come in between $275 million and $325 million; those adjusted EBITDA and revenue ranges imply an adjusted EBITDA margin of 9% at the midpoint of both ranges. To help put our outlook in context, I want to call out a few points. First, we expect the gross margin dynamics we saw in the second quarter to persist through the second half as branded weight loss offerings and international revenue continue to grow as the share of our business.

Yemi Okupe executive
#7

Like I said before, this change in our mix comes from a conscious choice to grow the specialties and markets that we think will create the platform's long-term value. Next, we anticipate that the cumulative impact of the weight loss groups we brought on during the first half will produce a significant increase in adjusted EBITDA dollars during the second half, along with ongoing leverage throughout our operating expenses as U.S. revenue growth picks up speed again. Meanwhile, we've built our guidance to keep the flexibility to push even harder into the investment priorities we've laid out today as opportunities arise. Last, we anticipate that our business outside the U.S. will bring in no less than $600 million of revenue in 2026, and it will keep running at or near breakeven on an adjusted EBITDA basis while we put scale first. Our platform delivers a blend of value to consumers that we think can't be matched anywhere else in health care. We're serving more health needs for our subscribers via an experience that grows more personal with each interaction, at prices that grow more affordable as we scale. That blend explains why more people are picking our platform than at any previous time, and why they remain longer, trusting us with more of their health. The most exciting part is that this has now become a genuinely global story. The re-acceleration happening in our U.S. business is matched by leadership positions across major international markets, which gives us more consumers to serve, more markets to scale and more ways to compound our advantages than at any other moment in our history. All of this strengthens our confidence in reaching our 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. We could not achieve this without the considerable efforts of Hims & Hers employees worldwide. I want to thank them, our subscribers and our shareholders for backing us in our mission to help the world feel great through the power of better health. With that, I'll now hand the call back to Bill to start Q&A with 2 questions from our retail community.

William Newby executive
#8

Appreciate that, Yemi. And I want to thank each person who submitted questions across the weekend. The Hims & Hers community sent in our opening question, and what they're hoping to get is a clearer picture of how we're thinking about the growing peptide opportunity. Their question is this: after the recommendations that came out of the July PCAC session regarding the 503A peptide list, could you share more specifics about the go-to-market time line once the FDA hands down final guidance? Given the California facility you already have, are you ready on the compliance side to launch in a matter of weeks, or do extra buildup steps exist that have moved this out to 2027? Also, do you still plan to let other players move first, or did the July recommendation alter that calculus?

Andrew Dudum executive
#9

Absolutely, and I appreciate you raising that. I've said before that this space as a whole — peptides along with wellness — is something I have a lot of enthusiasm for, and it was really encouraging to watch six out of seven make it through the PCAC meeting over at the FDA a few weeks ago. On your point about when this happens, our progress over the past two quarters has been remarkable, both on the clinical guidelines front and with the supply chain, and that's what gives me the conviction that should the FDA choose to reclassify these peptides onto the Category 1 list, we can act very fast. On the Hims side specifically, we've added Dr. Anant Vinjamoori as Chief Medical Officer — someone whose expertise spans hormonal therapy, longevity and peptide therapy. He has been putting together the clinical protocols, the guardrails, the dosing regimens and the provider training. Beyond that, at our API facility in Menlo Park, where we've made the commitment to manufacture the raw APIs here in the U.S. — something we believe is quite uncommon and that we're probably the sole company able to pull off — we're currently running BPC-157 through stability and validation testing so it's ready before long, with the rest to follow in sequence. So while we wait on the FDA's decisions and rulemaking, we'll keep pushing ahead in the wellness and peptide space with a wider range of products. That covers items such as sermorelin, glutathione, NAD+ and additional wellness therapies and injections, and our hope is to launch those by the close of this year.

William Newby executive
#10

Okay, thank you, Andrew. We have Tom T. up next, and his question was about the money we're putting into AI as well as the bigger-picture vision for what the experience for Hims & Hers customers might eventually look like. He wanted to know, when you consider labs, possible partnerships around wearables, and the treatment and outcome data being gathered from millions of customers, whether there's a plan to unify all of it, so that down the road a customer could view something akin to a real-time health score — with AI linking those data points, surfacing issues early, and suggesting next steps before they turn into actual problems — and how distant do you believe that kind of thing is? Also, is that something the team is actively building toward today?

Andrew Dudum executive
#11

Yes, that's essentially correct. We're in hiring mode as well. You can connect quite a few of those dots yourself, so go ahead and submit an application. But the real goal involves uniting every piece of 360-degree personal health — be it data from wearables, devices we make, devices from other companies, results from lab tests, labs we operate, labs elsewhere, right through to genetic analysis and preventive screenings — so that there's a whole ecosystem of physicians, specialists, coaches, agents, and pharmacists standing by for you around the clock, 24/7, actively watching for the best ways to help you live the healthiest, best life possible. As you might guess, this positions things nicely for a natural membership plan from Hims & Hers, arriving within the next year or 2. It also, I believe, lays the groundwork for a highly effective freemium option from Hims & Hers, letting patients simply come and use these tools at Hims & Hers at no cost, just to enjoy the advantages of a 360 view of their health — one unified platform plus an ecosystem, entirely driven by AI, sitting on top of a foundation of real physicians, real certified nutritionists, along with agents and care pilots. So if you zoom out, what we're creating is something already on the market. Today, most people would call this concierge care. It runs between $50,000 and $150,000 each year. Put most simply, my aim is to deliver that very same standard of proactive, preventative, always-on care affordably to everyone worldwide, at a price anybody can reach.

Maria Ripps analyst
#12

Maria, I want to bring up the Novo partnership, which clearly has performed very strongly on the volume side. The branded cohorts have now existed for a few quarters — they've had a couple of quarters to mature — so how do retention and engagement compare with what you've historically seen for other products? And beyond that, what's your thinking on making the Novo relationship deeper as you move forward?

Andrew Dudum executive
#13

Perhaps I could start with some general comments on the relationship and the opportunities, and then you can speak to retention and profiles. Maria, on a broad level, we couldn't be more pleased with how things are going with Novo Nordisk. Starting with Mike in the CEO role and extending throughout the organization, everyone has worked with us in a truly collaborative way to figure out how to expand patient access here in the United States. The launch of the Wegovy pill has been nothing short of remarkable. I believe we rank as the biggest, or among the biggest, companies helping individuals get their hands on that pill, and that has truly unlocked things for a lot of people who were worried about injections, hesitant about the cost, or had other concerns. So the domestic side of the relationship is very strong. Beyond that, our international ties are also exceptionally strong, and many of those connections come from the Eucalyptus acquisition we made. This happened throughout Germany and the U.K., where we managed to build up wait lists containing tens of thousands of people for the Wegovy pill in only a matter of days in certain of those markets while they were preparing to launch. I believe collaboration is growing when it comes to important strategic markets that matter to both companies, and there's a lot of thought going into working together to grow the market and improve access for people. I believe we're getting better and better at exchanging information about which treatments are effective for patients, the advantages when it comes to adherence, and what shows up regarding adverse reactions or ways to reduce them through various dosing schedules. So once the top pharmaceutical companies begin moving nearer to real-world consumer information — information that supports not just the promotion of existing treatments but also our thinking about how new treatments reach the market — I see a genuinely potent momentum loop forming here. And because of that, I believe the number of possibilities keeps expanding, and I think both teams feel a great deal of enthusiasm about them.

Yemi Okupe executive
#14

As for the other half of what you asked, Maria. Honestly, retention is coming in where we expected it to. The Q2 beat — a significant portion of it — came about largely because the weight category, along with some others, performed far more strongly than we had anticipated. Once we observed that, it gave us the confidence to raise guidance for the remainder of the year. What might be even more thrilling on our end is watching the experience keep improving. During the prepared remarks, we discussed how a richer, more immersive experience — via the app's next iteration, certain AI tools, and physical tools such as the scale that consumers are receiving — allows for greater connectivity with their providers; and in the end, we are already noticing indications of reduced cancellation rates among the user cohorts that get that. And as we aim to keep putting investment into the experience, and spot chances as we capture additional efficiencies to bring price points within easier reach, we observe a retention rate that is already strong becoming ever more robust.

Ryan MacDonald analyst
#15

Ryan, thanks for the kind words about the quarter. So as we're bringing Eucalyptus into the fold and looking at the international deals we've closed, you're asking which specialty areas are really clicking in those overseas markets, and where we think the easiest wins are for widening assortment there — especially for eucalyptus, which already has a lot of strength in the U.S.

Andrew Dudum executive
#16

Yes, good question, Ryan. One thing I'd point to: Eucalyptus in particular has built genuine dominance in the U.K., Australia and Germany, and more recently in Japan and Canada, in the weight loss category. They serve that demographic extremely well — among the top providers, maybe the top, in those markets, and taken together, the top digital health providers there. Where I think real opportunity lies is in taking some of the core specialties that Hims & Hers has mastered here at home and moving them abroad. That covers things such as testosterone replacement therapy and menopause therapy for women. It's basic assortment in dermatology areas like men's and women's hair, men's and women's sexual health and reproductive health, plus categories like peptides in certain of those markets, where regulatory openings differ and let patients access some of these more cutting-edge longevity therapies. So at a very high level, I'd say there's some very easy picking in bringing the best, highest performing, and even some of the fastest growing categories — like testosterone — that we have domestically into at least 5 or 6 markets overseas, using the engine and the go-to-market commercial strategy the Eucalyptus team is already well set up to execute.

Ryan MacDonald analyst
#17

Thanks for that. Then, to follow up, perhaps I could get one thing cleared up regarding the peptides. I realize you touched on this somewhat when answering an earlier question, and mentioned all the work being done in that area. But regarding the timing — or rather, the trigger you're anticipating — is it the complete official FDA guidance currently in the register, which may require something like a 6- to 12-month procedure, that you'd wait for before beginning to sell those 6 out of the 7? Or would the mere launch of the proposed rule-making, with its comment period and so forth, serve as the indication of a closer-term chance for you to begin selling those 6 approved peptides?

Andrew Dudum executive
#18

Yes. Ryan, thank you for seeking that clarification. As we operate right now, we are awaiting the FDA's full and final rule making; that might arrive in numerous shapes and circumstances, and it might arrive on varying schedules. Still, we believe it's truly essential that they finish that process prior to our launching this product.

Mark Mahaney analyst
#19

Mind if I ask a couple of things? It's about what Eucalyptus adds in the second half. To start, regarding that downward tweak to the EBITDA outlook for the whole year — I realize you brought up spending on AI plus more growth abroad. But does Eucalyptus dilution factor into that lower EBITDA growth figure for the full year? Then, about the U.S. pickup you witnessed in Q2 and brought up — I believe your guidance for the remaining half implies it. And I think that mostly comes from widening the weight loss options you offer. Could you — would you help us put a number on how much additional acceleration might come in the back half?

Yemi Okupe executive
#20

Yes. Appreciate that, Mark. I'll handle the second one, since it's really the driver behind the first. So in the U.S., we anticipate strong acceleration for both revenue and EBITDA across the back half. Truly, a handful of items are behind that push. Number one, with the shift — especially for branded products — to a monthly rhythm, you begin seeing more cohort stacking from subscribers staying longer with what the platform offers. That naturally produces higher revenue and EBITDA alike. So we'd look for those impacts to begin compounding in Q3 and Q4 both. You already witnessed some of that via an acceleration of about 12 points in the first quarter. I believe that will compound as the experience improves through certain elements Andrew brought up, plus what Mo said during the prepared remarks regarding AI and some tools subscribers will have at their disposal; naturally, our belief is that stronger retention capability will grow, pushing that acceleration even more. Still, what we observe is that as efficiencies appear throughout the portfolio — in the U.S. and notably from early savings AI is giving us — those get reinvested into really 2 places. First, we take part of those savings and put them toward a richer weight experience that delivers more value to consumers. That might mean making price points easier to reach. It might also mean adding more tools and simply working out how to boost stickiness on the platform. The second place we're ready to put money is where we see a chance to lock in leadership across numerous areas, especially in appealing markets in Western Europe such as the U.K., Germany, and Canada — using the strength of the U.S. and domestic portfolio to push hard there, which our guidance reflects. So our guidance allows for the flexibility to make price points easier to reach here at home, and also to invest whenever opportunities match our capital allocation standards of a breakeven period of 1 year or less. We'll pursue those, especially throughout international markets.

Craig Hettenbach analyst
#21

Regarding the effort to increase AI usage, is there anything particular about beginning on the Hers side, and then roughly when should we expect that to appear on the Hims side too?

Andrew Dudum executive
#22

Yeah. Craig, thanks for asking. As we mentioned in the prepared remarks, we're extremely enthusiastic about this. On the Hers side, I think we're seeing significant growth in engagement. With the new care operating plan and operating system we've introduced, patients are now interacting and messaging with their care teams 3x as much. Meanwhile, the number of tasks actually handled by humans has fallen 50% for nonclinical work. So this is a really uncommon mix of very high engagement — which we know delivers long-term downstream advantages for reducing cancellations and improving retention — plus genuine cost savings that, as Yemi noted, we can instantly put back into more aggressive pricing and opportunities to capture market share in the weight category and the international category. We began with the women's weight loss business since it's among the highest-engagement areas of the business. In that category, there are a huge number of questions. There's enormous complexity around fears of injections, dosing schedules, and managing side effects. It's just — it's likely the most complicated category we're in right now; so we figured building the operating system and this kind of AI platform that links pharmacists, a doctor, care coaches, and agents together in that setting was the ideal place to begin. We're moving quickly to introduce this in other markets. As we've said, we intend to launch some of the other therapies and peptides that are already on the Category 1 list, and to broaden the TRT offering with injectable testosterone and oral testosterone; the goal is for this new AI-powered experience to support some of those new category launches on the Hims side as they arrive over the next couple of quarters.

Craig Hettenbach analyst
#23

That's useful. Then, Andrew, a fast follow-up: as you accelerate with fresh product lines — you've mentioned every one of the tech capabilities in AI plus the reach and the capacity — how do you decide which of these new categories comes first? Do you have any thresholds or market-based criteria that give some of these new categories a green light, while others perhaps end up taking longer before launch?

Andrew Dudum executive
#24

Yes, Craig, excellent question. We now operate at a scale of almost 3 million subscribers worldwide, and at that point patients do a wonderful job showing us where the business and the clinical needs are. Truly central to this strategy, then, was the lab testing infrastructure we bought and have introduced over the past few quarters, which will be packaged alongside many of those categories we just discussed and, in effect, come at no cost with your care. What that adoption has revealed tells us precisely where we ought to head. We're moving into metabolic health, with a wider set assortment on the GLP-1 side. We're moving into hormonal health, since on both men and women we observe enormous overlap among those patient populations, and we're moving into sleep and recovery and a longevity focus, since that's what people report to our providers — that they're interested in it or having difficulty with it. So we sit at this incredibly potent spot in the flywheel, where the business's scale and the strong engagement we get from patients on individual categories genuinely fuel and speed up how we grasp new categories, how we grasp the cross-sell potential of those categories, and in the end what the overlap will be. Over time, I believe, that assortment and that breadth amount to a huge competitive advantage. As we noted in the remarks, with testosterone we're nearing 6 categories, expanding past a $100 million run rate. That assortment, I think, will keep speeding up how quickly we can bring new things to market and how quickly they reach that $100 million run rate threshold, simply because existing patient populations will inform them far better, with much clearer targeting and the ability to bridge patients toward more comprehensive care.

Eric Percher analyst
#25

Eric, I want to pick up on what you said regarding those 3 million subscribers. What I'd find valuable is your take on the latest expansion — how much of it reflects a bolus of demand that had been sitting on the sidelines, versus our capacity to sustain that pace. Then, Yemi, I'd also like to confirm whether the quarter-over-quarter increase we recorded meaningfully incorporates Eucalyptus subscribers.

Andrew Dudum executive
#26

Yes, excellent question, Eric. On the Eucalyptus piece, I'll turn it over to Yemi. In my view, a substantial share of this stemmed from the business pivoting toward a broader set of offerings in weight loss, adding certain newer therapies to the platform. Demand for these therapies is, clearly, enormous. And by structuring our business model so that we enjoy tight, mutually advantageous ties with the major pharmaceutical players and the big biotech firms, we should keep enabling this kind of faster growth whenever new therapies reach the market — where customers feel excitement and real commercial opportunity exists. Beyond that, I'd point to renewed momentum across categories. The men's hormonal segment stands out: in merely a couple of quarters, it has turned into our quickest-expanding business apart from weight loss, and before long we'll be crossing that $100 million mark. So we keep pressing further into that category, widening the assortment there, and taking it internationally. Broadly speaking, it's a solid mix: the business model, more strong choices on the metabolic side, plus the legacy core Hims business picking up speed again as we direct greater attention toward these newer initiatives.

Yemi Okupe executive
#27

Regarding the latter portion of what you asked, Eric: for Eucalyptus, both the top line and the bottom line show up within the second quarter's numbers. Where revenue is concerned, that's approximately $40 million attributable to Eucalyptus, and on the whole, the material piece sitting behind the guidance is essentially just domestic revenue that keeps accelerating. Within the weight category, the assortment has clearly acted as a catalyst enabling us to speed up the trajectory for both revenue and subs in that area, yet beyond that, on the Hims side too, as we keep seeing success with offerings such as the low testosterone one along with some of our other newer specialties, once those scale, we keep watching the domestic business flourish, which hands us more dry powder to put into the international markets.

Glen Santangelo analyst
#28

I've got two quick items. Yemi, I'd like to build on what Eric asked about Eucalyptus. Previously, you mentioned that Eucalyptus was producing roughly a breakeven margin at that time. Does that remain true? And is there anything more you can share on that? My second item concerns margins over the longer term. Looking at your 3Q guidance, the margins implied for the fourth quarter, I believe you're guiding to 12% EBITDA margins, or 12% at the midpoint. Have I got that right? And does it make sense to treat that as a starting point for thinking about fiscal '27, recognizing that's still several months off? I know you'd prefer not to comment much on fiscal '27. But I'm simply trying to work out the margin path, since you're effectively reaffirming that 20% margin in 2030. Whatever perspective you could offer on how we ought to approach that would be useful.

Yemi Okupe executive
#29

Yes. Appreciate that, Glen. Addressing the first portion of what you asked, regarding Eucalyptus, my sense is they were operating at approximately breakeven, perhaps with modest losses. As we observe ongoing momentum in the U.S., international markets represent something we're ready to pursue in a deliberate manner. Taken together, our expectation is that those will be close to or at breakeven. Yet when chances arise, I'd say that's among the great aspects of the domestic and — the strongest domestic acceleration we're witnessing, which creates room to put money to work there. On what you asked next, regarding the margin profile over the longer term, I'm not in a position to address 2027 at this stage, though we're essentially refocusing on what our approach will be across the coming couple of quarters while we keep leaning in and investing. And truly, that aims at, above all, generating robust free cash flow along with robust EBITDA dollar generation overall. So you can observe that the layering of the cohorts, especially within the weight loss segment we discussed previously, along with certain advantages arising from the ramp in newer specialties that Andrew brought up, those factors provide us confidence to invest boldly while still producing robust cash flow and EBITDA dollars.

Operator operator
#30

That brings our question-and-answer portion to a close. Today's call ends here. We appreciate your participation. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Hims & Hers Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Hims & Hers Health, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.